AU2007217770B2 - New crystal forms and pharmaceutical compositions of (+) -R-zileuton - Google Patents

New crystal forms and pharmaceutical compositions of (+) -R-zileuton Download PDF

Info

Publication number
AU2007217770B2
AU2007217770B2 AU2007217770A AU2007217770A AU2007217770B2 AU 2007217770 B2 AU2007217770 B2 AU 2007217770B2 AU 2007217770 A AU2007217770 A AU 2007217770A AU 2007217770 A AU2007217770 A AU 2007217770A AU 2007217770 B2 AU2007217770 B2 AU 2007217770B2
Authority
AU
Australia
Prior art keywords
zileuton
crystalline form
single crystalline
pharmaceutical composition
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007217770A
Other languages
English (en)
Other versions
AU2007217770A1 (en
Inventor
Jason A. Hanko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi USA Inc
Original Assignee
Cornerstone Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornerstone Therapeutics Inc filed Critical Cornerstone Therapeutics Inc
Publication of AU2007217770A1 publication Critical patent/AU2007217770A1/en
Application granted granted Critical
Publication of AU2007217770B2 publication Critical patent/AU2007217770B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007217770A 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+) -R-zileuton Ceased AU2007217770B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77557906P 2006-02-21 2006-02-21
US60/775,579 2006-02-21
PCT/US2007/004488 WO2007098189A2 (en) 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+) -r-zileuton

Publications (2)

Publication Number Publication Date
AU2007217770A1 AU2007217770A1 (en) 2007-08-30
AU2007217770B2 true AU2007217770B2 (en) 2011-09-08

Family

ID=38437967

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007217770A Ceased AU2007217770B2 (en) 2006-02-21 2007-02-21 New crystal forms and pharmaceutical compositions of (+) -R-zileuton

Country Status (6)

Country Link
US (1) US8003684B2 (enExample)
EP (2) EP2001861A2 (enExample)
JP (1) JP2009527484A (enExample)
AU (1) AU2007217770B2 (enExample)
CA (1) CA2642216A1 (enExample)
WO (1) WO2007098189A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
CA2674492A1 (en) * 2007-01-05 2008-07-17 Cornerstone Therapeutics Inc. Method for the treatment of conditions associated with increased 5-lipoxygenase and/or leukotriene activity
WO2009045291A2 (en) 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
NZ807894A (en) 2009-04-29 2025-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2959899B1 (en) * 2011-08-23 2017-02-22 Cornerstone Therapeutics Inc. Use of zileuton for the treatment of nasal polyps in cystic fibrosis patients
KR101462474B1 (ko) * 2013-10-30 2014-11-19 주식회사 큐리언트 질레우톤 크림 제형의 국소용 항염증 약학적 조성물
US9855243B2 (en) 2013-10-30 2018-01-02 Qurient Co., Ltd. Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation
AU2015276857B2 (en) * 2014-06-20 2017-10-19 Vaxart, Inc. Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279263B1 (en) * 1987-02-10 1993-08-04 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
WO1994026268A1 (en) * 1993-05-10 1994-11-24 Sepracor, Inc. Methods and compositions using optically pure (+)-zileuton

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US279263A (en) * 1883-06-12 Eobeet t
US5663368A (en) 1993-07-14 1997-09-02 Smithkline Beecham Corporation Synthesis of acid addition salts of hydroxylamines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279263B1 (en) * 1987-02-10 1993-08-04 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
WO1994026268A1 (en) * 1993-05-10 1994-11-24 Sepracor, Inc. Methods and compositions using optically pure (+)-zileuton

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHANG, Z.L., Analytical Profiles of Drug Substances and Excipients, 1998, vol. 15, pages 535-575 *

Also Published As

Publication number Publication date
WO2007098189A2 (en) 2007-08-30
US8003684B2 (en) 2011-08-23
CA2642216A1 (en) 2007-08-30
AU2007217770A1 (en) 2007-08-30
JP2009527484A (ja) 2009-07-30
EP2001861A2 (en) 2008-12-17
US20070244185A1 (en) 2007-10-18
EP2409973A1 (en) 2012-01-25
WO2007098189A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
AU2007217770B2 (en) New crystal forms and pharmaceutical compositions of (+) -R-zileuton
CA2674347C (en) Solid state forms of racemic ilaprazole
JP6076267B2 (ja) リファキシミンの形態およびその使用
TW202128617A (zh) 三苯化合物之新穎鹽類
JP2023547959A (ja) Ｂｃｌの結晶性固体メグルミン塩阻害物質、並びに前記阻害物質を作製及び使用する方法
CN112135832A (zh) 化合物的晶型和制备化合物的晶型的方法
WO2001072750A1 (en) Novel crystal form of pyrrolidylthiocarbapenem derivative
TWI540131B (zh) 阿瑞吡坦（ａｐｒｅｐｉｔａｎｔ）ｌ－脯胺酸組成物及共晶體
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
TW200900392A (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same
JP2019512542A (ja) 結晶塩形態
US10004750B2 (en) Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
US11466008B2 (en) Co-crystals of neflamapimod (VX-745)
ES2926790T3 (es) Solvato de dietilamina del inhibidor del transportador de sodio-glucosa, y método de preparación y aplicación del mismo
WO2010111951A1 (zh) 普拉格雷氢溴酸盐的晶体
US20130012479A1 (en) Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
US20250197393A1 (en) Integrin inhibitor and uses thereof
US8710078B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
KR20180124428A (ko) 결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물
US9102657B2 (en) Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
KR20180124400A (ko) 사쿠비트릴 결합체, 이의 제조방법 및 이를 포함하는 약학 조성물
TW200302830A (en) Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN116813542A (zh) 米力农的药物多晶体
JP2022514624A (ja) Ｐａｒ４阻害剤の結晶体
NZ620864B2 (en) Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired